Geron faces uphill battle at FDA meeting as agency questions benefit-risk profile of imetelstat.

With 99% of patients having an adverse event, the FDA is skeptical that the benefit of Geron's MDS medicine imetelstat outweighs the risks. [ABSTRACT FROM AUTHOR]